Growth & profitability
- Revenue has grown 6.7% per year over the past 5 years.
- Operating margin has contracted, at -8.7% in the latest year.
- Free cash flow has declined 19.4% per year over the past 5 years.
SUPN Financials Supernus Pharmaceuticals, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $719M | -$39M | 89.6% | -8.7% | $46M | — | $128M |
| 2024 | $662M | $74M | 88.2% | 12.3% | $171M | — | $69M |
| 2023 | $608M | $1M | 86.2% | -0.9% | $111M | — | $75M |
| 2022 | $667M | $61M | 86.9% | 6.9% | $116M | — | $93M |
| 2021 | $580M | $53M | 0.0% | 14.8% | — | $379M | $203M |
| 2020 | $520M | $127M | 89.9% | 33.4% | $135M | — | $289M |
| 2019 | $393M | $113M | 95.8% | 37.8% | $140M | — | $181M |
| 2018 | $409M | $111M | 96.2% | 35.3% | $128M | — | $192M |
| 2017 | — | $57M | — | — | $113M | — | $100M |
| 2016 | — | $91M | — | — | $65M | — | $66M |
| 2015 | — | $14M | — | — | $32M | — | $33M |
| 2014 | — | -$11M | — | — | -$25M | — | $36M |
| 2013 | — | -$92M | — | — | -$60M | — | $33M |
| 2012 | — | -$46M | — | — | -$48M | $23M | $40M |
| 2011 | — | $54M | — | — | -$37M | — | $49M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $208M | -$2M | 88.7% | -4.0% | $67M | — | $185M |
| Dec '25 | $212M | -$4M | 89.1% | -1.9% | $19M | — | $128M |
| Sep '25 | $192M | -$45M | 90.1% | -31.4% | -$62M | — | $151M |
| Jun '25 | $165M | $22M | 89.8% | 7.3% | $58M | — | $145M |
| Mar '25 | $150M | -$12M | 89.5% | -6.8% | $30M | — | $116M |
| Dec '24 | $174M | $15M | 85.0% | 12.3% | $44M | — | $69M |
| Sep '24 | $176M | $38M | 90.0% | 23.2% | $53M | — | $32M |
| Jun '24 | $168M | $20M | 89.4% | 13.4% | $36M | — | $52M |
| Mar '24 | $144M | $124000 | 88.6% | -2.2% | $38M | — | $63M |
| Dec '23 | $164M | $1M | 88.1% | -0.6% | $45M | — | $75M |
| Sep '23 | $154M | -$16M | 87.3% | 5.3% | $36M | — | $95M |
| Jun '23 | $136M | -$831000 | 84.4% | -13.0% | -$19M | — | $25M |
| Mar '23 | $154M | $17M | 84.7% | 3.4% | $49M | — | $58M |
| Dec '22 | $167M | $25M | 0.0% | 20.5% | — | — | $93M |
| Sep '22 | $177M | $2M | 85.4% | -0.9% | $14M | $401M | $111M |
| Jun '22 | $170M | $8M | 88.0% | 6.7% | $72M | $401M | $173M |
| Mar '22 | $153M | $26M | 88.2% | 1.3% | $3M | — | $116M |
| Dec '21 | $159M | $2M | 0.0% | 3.8% | — | $379M | $203M |
| Sep '21 | $148M | $22M | 87.8% | 22.0% | — | — | $215M |
| Jun '21 | $141M | $24M | 82.3% | 24.1% | $46M | — | $224M |
Valuation over time
How the market has priced SUPN against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has risen from 34.6× (Mar '23) to 35.8× (Nov '25).
- The price-to-sales ratio has risen from 3.1× (Mar '23) to 3.6× (Jun '26).
P/E
P/S
Frequently asked questions
Is SUPN growing its revenue and profit?
Over the past 5 years, Supernus Pharmaceuticals, Inc.'s revenue has grown 6.7% per year. These are computed facts, not advice.
How much debt does SUPN have?
As of FY2025, Supernus Pharmaceuticals, Inc. reported — of total debt against $128M of cash.
What is SUPN's profit margin?
In FY2025, gross margin was 89.6%, operating margin -8.7%, and net margin -5.4%.
What is SUPN's P/E ratio?
As of Jun '26, Supernus Pharmaceuticals, Inc. traded at a price-to-earnings ratio of about 35.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.